L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for Sunshine Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:43 pm Purchase |
2024-12-31 | 13G | Sunshine Biopharma, Inc. SBFM |
L1 Capital Global Opportunities Master Fund, Ltd. | 142,244 4.990% |
139,601 (+5282.21%) |
Filing |
| 2024-02-23 4:03 pm Purchase |
2024-02-13 | 13G | Sunshine Biopharma, Inc. SBFM |
L1 Capital Global Opportunities Master Fund, Ltd. | 2,643 5.300% |
2,643 (New Position) |
Filing |